Physician profile
Jennifer Wilhelm
NPI 1427320100
$1,482.31
in general payments reported to CMS, 2019-2025
18 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.68 · 2022: $191 · 2023: $270 · 2024: $748 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $561.01 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $217.56 | 2023-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $92.45 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $88.05 | 2023-2025 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $67.92 | 2024-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $64.28 | 2023-2024 | Dyanavel Xr |
| Corium, LLC | $57.79 | 2023-2024 | Azstarys |
| Vertical Pharmaceuticals, LLC | $47.40 | 2024 | Relexxii |
| Alkermes, INC. | $46.30 | 2023-2024 | Aristada, Lybalvi |
| Tempus Ai, INC | $43.40 | 2024 | Tempus Pixel |
| E.R. Squibb & Sons, L.L.C. | $39.94 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.00 | 2024 | Caplyta |
| Boston Scientific Corporation | $29.15 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.19 | 2023 | Invega Trinza, Invega Sustenna |
| Indivior INC. | $22.68 | 2023 | Perseris |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $16.52 | 2022 | |
| Lundbeck LLC | $14.89 | 2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $14.78 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Wilhelm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.